These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29205808)

  • 41. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
    Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aptamers with Self-Loading Drug Payload and pH-Controlled Drug Release for Targeted Chemotherapy.
    Zeng Z; Qi J; Wan Q; Zu Y
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma.
    Rassidakis GZ; Drakos E
    Front Biosci (Elite Ed); 2016 Jan; 8(1):61-71. PubMed ID: 26709646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
    Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
    Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
    Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
    Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases.
    Yu BH; Zhang Y; Xue T; Shui RH; Lu HF; Zhou XY; Zhu XZ; Li XQ
    Diagn Pathol; 2021 Jan; 16(1):1. PubMed ID: 33402163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
    Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
    Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
    Carnesecchi S; Rougemont AL; Doroshow JH; Nagy M; Mouche S; Gumy-Pause F; Szanto I
    Free Radic Biol Med; 2015 Jul; 84():22-29. PubMed ID: 25797883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics And Outcomes Of Anaplastic Large Cell Lymphoma Patients-A Single Centre Experience.
    Athar S; Siddiqui N; Hameed A
    J Ayub Med Coll Abbottabad; 2017; 29(1):37-41. PubMed ID: 28712170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
    Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
    Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
    Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
    Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
    Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
    Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
    Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
    ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PrP
    Go G; Lee CS; Yoon YM; Lim JH; Kim TH; Lee SH
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.